Literature DB >> 27998619

How do you decide on hormone replacement therapy in women with risk of venous thromboembolism?

Danijela Lekovic1, Predrag Miljic2, Aleksandar Dmitrovic3, Jecko Thachil4.   

Abstract

Women are increasingly encouraged to participate in making decisions about hormone replacement therapy (HRT). In postmenopausal women with severe vasomotor symptoms, HRT can significantly improve the quality of life. However, the use of HRT may also increase the risk of venous thromboembolism (VTE), the risk which depends of both treatment-related and patient-related factors. This review summarizes some important points about the selection of the safest hormonal replacement modality in women with a history of VTE and management of VTE risks in postmenopausal women wishing to take HRT.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hormone replacement therapy; Menopause; Venous thromboembolism

Mesh:

Substances:

Year:  2016        PMID: 27998619     DOI: 10.1016/j.blre.2016.12.001

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  1 in total

1.  Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia.

Authors:  Isabel Ramírez; Esther De la Viuda; Laura Baquedano; Pluvio Coronado; Plácido Llaneza; Nicolás Mendoza; Borja Otero; Sonia Sánchez; Mª Jesús Cancelo; José Antonio Páramo; Antonio Cano
Journal:  Maturitas       Date:  2020-05-06       Impact factor: 4.342

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.